Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$11.49 USD
-0.15 (-1.29%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.53 +0.04 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Intellia Therapeutics, Inc.'s return on equity, or ROE, is -56.06% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that NTLA has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
NTLA 11.49 -0.15(-1.29%)
Will NTLA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NTLA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NTLA
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
NTLA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Take the Zacks Approach to Beat the Markets: AngloGold Ashanti, Caterpillar & Hershey in Focus
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
Other News for NTLA
NTLA Awards Inducement Grant Amid Employment Expansion
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA ...
Intellia Therapeutics announces employee inducement grants
Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options